Media headlines about Cyberonics (NASDAQ:CYBX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cyberonics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.8363874992678 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Cyberonics, Inc is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD).
Receive News & Ratings for Cyberonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyberonics and related companies with MarketBeat.com's FREE daily email newsletter.